Week In Review: Betta Pharma Enters $392 Million Deal For C4 Therapeutics’ NSCLC Drug

Hangzhou Betta Pharma acquired greater China rights for a novel non-small cell lung cancer drug from Boston’s C4 Therapeutics in a deal worth up to $392 million. Additionally, Lynk Pharma of Hangzhou raised $28 million in a Series C1 financing.